Enjoy complimentary customisation on priority with our Enterprise License!
The pulmonary edema therapeutics market size is forecast to increase by USD 365.5 million, at a CAGR of 3.27% between 2023 and 2028. The growth of the market is influenced by several key factors. Firstly, the high prevalence of risk factors such as hypertension, diabetes, and obesity contributes significantly to the incidence of pulmonary edema, driving the demand for advanced diagnostic tools and therapeutic interventions. Secondly, the increasing geriatric population worldwide is prone to developing respiratory conditions, including pulmonary edema, thereby expanding the market for healthcare solutions tailored to elderly care. Additionally, growing awareness about pulmonary edema among healthcare professionals and the general population fosters early diagnosis and prompt treatment, further stimulating market growth. These factors collectively underscore the importance of continuous innovation in medical technologies and treatments, as well as targeted healthcare initiatives to address the rising healthcare burden associated with pulmonary edema.
For More Highlights About this Report, Request Free Sample
Pulmonary edema is a potentially life-threatening condition characterized by the accumulation of excess fluid in the lungs, impairing the ability to breathe effectively. This condition is often a complication of heart failure, where the heart is unable to pump blood efficiently, leading to a backup of fluid in the lungs. The geriatric population is particularly vulnerable to pulmonary edema due to age-related cardiovascular changes. Heart treatments are the primary therapeutic approach for managing pulmonary edema. These include medications such as diuretics, vasodilators, and inotropes, which help reduce fluid buildup and improve heart function. Supplemental oxygen is also used to support breathing and improve oxygenation. Diagnostic evaluations, such as chest X-rays, echocardiograms, and pulmonary function tests, are crucial for diagnosing pulmonary edema and assessing the underlying biological state of the disease process.
Biomarkers, such as natriuretic peptides, can also aid in diagnosis and prognosis. Risk factors for pulmonary edema include hypertensive crisis, lung disorders, and cardiac issues. Chronic conditions like chronic heart failure and acute conditions like ARIC (Acute Coronary Insufficiency) and CHS (Coronary Heart Disease) can lead to pulmonary edema. Intra-ventricular septum defects and pulmonary shunts can also contribute to the condition. Lungs are essential organs responsible for breathing, and their proper functioning is crucial for maintaining overall health. Pulmonary edema disrupts the normal functioning of the lungs by filling the air sacs with fluid, making it difficult to breathe. The prognosis for pulmonary edema depends on the underlying cause and timely intervention with appropriate treatments.
The high prevalence of risk factors is notably driving market growth. Pulmonary edema is a life-threatening disease process characterized by the accumulation of fluid in the lungs, leading to difficulty breathing. The condition can be caused by various factors, including infections, organ failures, and lifestyle habits. Infections, such as bacterial, viral, fungal, and those related to the blood, are the most common causes of pulmonary edema. For instance, Respiratory Syncytial Virus (RSV) affects approximately 64 million people annually, leading to around 160,000 deaths worldwide. Other risk factors include cardiac disorders like heart valve problems, cardiomyopathy, and cardiovascular diseases, such as high blood pressure, coronary artery disease, and carotid artery disease. The disease can also be caused by drug-induced injury to the capillary endothelium or drugs depressing the central nervous system, resulting in neurogenic pulmonary edema.
Moreover, the diagnosis of pulmonary edema involves clinical examination, imaging testing, and blood tests. The market for pulmonary edema therapeutics is driven by the high prevalence of these risk factors and the need for effective treatments. Healthcare systems and pharmaceutical companies invest heavily in the research and development of drugs, vaccines, and devices to address this condition. The therapeutic areas include immunology, oncology, cardiology, endocrinology, and neurology. The supply chain includes wholesalers, retailers, hospitals, clinics, and pharmacies. Infrastructure and healthcare investments are crucial to ensure the availability and accessibility of these therapeutic products. Thus, such factors are driving the growth of the market during the forecast period.
Increasing use of biomarkers for disease diagnosis is the key trend in the market. Pulmonary edema is a potentially life-threatening condition characterized by the accumulation of excess fluid in the lungs. This disease process can be diagnosed through a combination of clinical examination, imaging testing, and blood tests. Clinical evaluation involves assessing symptoms such as shortness of breath, coughing, and chest pain. Imaging tests, such as chest X-rays and echocardiograms, can help visualize the fluid buildup in the lungs and assess the function of the heart. Blood tests play a crucial role in diagnosing pulmonary edema by identifying specific biomarkers. For instance, the serum brain natriuretic peptide (BNP) or N-terminal-pro BNP (NT-pro-BNP) and plasma CD146 cardiac markers are collected through blood tests. Elevated levels of these markers indicate the presence of heart failure, which can lead to pulmonary edema. Cardiac disorders, including cardiomyopathy, heart valve problems, and hypertension, are common causes of pulmonary edema.
Other conditions, such as kidney disorders, carotid artery disease, and infection, can also contribute to the development of this condition. Healthcare systems invest heavily in infrastructure and pharmaceutical products to address the growing burden of cardiovascular diseases, including pulmonary edema. The supply chain for pulmonary edema therapeutics involves various stakeholders, including medical disciplines such as immunology, oncology, cardiology, endocrinology, and neurology. Pharmaceutical companies develop drugs and vaccines to treat the underlying causes of pulmonary edema, while wholesalers, retailers, hospitals, clinics, and pharmacies distribute and administer these treatments. Ventilator-assisted respiration may be necessary for severe cases, and healthcare investments in infrastructure and technology are essential to ensure access to these advanced therapies. Thus, such trends will shape the growth of the market during the forecast period.
Adverse effects of available therapeutics is the major challenge that affects the growth of the market. The market encompasses a range of drugs and devices used in the treatment of various cardiovascular and kidney disorders, including cardiac disorders such as heart failure, cardiovascular diseases like hypertension and carotid artery disease, heart valve problems, cardiomyopathy, and infection-related pulmonary edema. Clinical examination, imaging testing, and blood tests are essential for diagnosing these conditions. The market includes pharmaceutical products, such as diuretics like Furosemide (LASIX), which are commonly used to manage symptoms of pulmonary edema. However, the use of these drugs comes with potential adverse effects, including mild symptoms like headache, fever, chills, nausea, and vomiting, as well as serious side effects such as dehydration and electrolyte imbalances.
In addition, healthcare systems invest heavily in infrastructure and health care to ensure the availability of these therapeutics. The therapeutic areas of immunology, oncology, cardiology, endocrinology, and neurology all contribute to the market's portfolio. The supply chain includes wholesalers, retailers, hospitals, clinics, and pharmacies. The market's growth is influenced by the increasing prevalence of high-risk factors, such as high blood pressure and coronary artery disease. However, the market faces challenges due to the adverse effects of existing treatments and the need for continuous innovation to address these challenges. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers FIRAZYR which is a bradykinin B2 receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The cardiogenic pulmonary edema segment is estimated to witness significant growth during the forecast period. Pulmonary edema is a disorder characterized by the accumulation of fluid in the lungs, leading to impaired breathing and cardiac issues. Cardiogenic pulmonary edema, the most common type, arises from heart failure due to cardiac insufficiency, specifically left ventricular dysfunction. This condition results in increased pressure within the heart chambers, causing a backup of fluid in the lungs. The geriatric population is particularly susceptible to heart failure and, consequently, cardiogenic pulmonary edema. The National Heart, Lung and Blood Institute, along with research initiatives such as the ARIC and CHS studies, have been instrumental in advancing our understanding of this disorder. Cardiogenic pulmonary edema is diagnosed through various diagnostic evaluations, including arterial blood gas analysis, chest X-rays, and echocardiograms.
Get a glance at the market share of various regions Download the PDF Sample
The cardiogenic pulmonary edema segment was the largest and was valued at USD 1.33 billion in 2018. Treatment options include diuretics like LASIX, EDECRIN, and ALDACTONE, as well as vasodilators such as NITROPRESS. Non-cardiogenic pulmonary edema, another type, can be caused by various factors, including hypertensive crisis, respiratory syndrome coronavirus, and pulmonary shunts. Treatment for non-cardiogenic pulmonary edema may involve supplemental oxygen, medicines, and supportive care. The market encompasses retail pharmacies, hospital pharmacies, and online pharmacies as distribution channels. Market growth is driven by disease control initiatives, joint ventures, acquisitions, mergers, and collaborations. Biomarkers play a crucial role in diagnosing and monitoring the progression of pulmonary edema. The prognosis for pulmonary edema depends on the underlying cause and the timely administration of appropriate drugs.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Heart failure, a cardiovascular disorder characterized by the inability of the heart to pump blood effectively, can lead to pulmonary edema. This condition is marked by an accumulation of fluid in the lungs, causing shortness of breath and difficulty in breathing. The geriatric population is particularly susceptible to heart failure and pulmonary edema due to age-related cardiac issues and other comorbidities. The National Heart, Lung and Blood Institute, along with various research initiatives like the ARIC and CHS studies, are dedicated to advancing heart treatments for cardiovascular failure and pulmonary edema. These conditions can be classified into cardiogenic and non-cardiogenic types, with cardiogenic pulmonary edema resulting from heart dysfunction and non-cardiogenic pulmonary edema stemming from various causes such as respiratory syndrome coronavirus or hypertensive crisis. Pulmonary edema therapeutics encompass a range of treatments, including medicines, supplemental oxygen, and diagnostic evaluations. Biomarkers play a crucial role in diagnosing and monitoring the progression of pulmonary edema.
Retail pharmacies, hospital pharmacies, and online pharmacies provide access to these treatments. Disease control strategies, such as joint ventures, acquisitions, and mergers, are also prevalent in the market. The lungs, as vital organs responsible for breathing, consist of air sacs that can become filled with fluid in pulmonary edema. This condition can be acute or chronic, with varying prognoses depending on the underlying cause and timely intervention. Intra-ventricular septum displacement and arterial blood gas evaluations are essential diagnostic tools in managing pulmonary edema.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
Pulmonary edema is a serious condition characterized by the accumulation of excess fluid in the lungs, leading to difficulty breathing and cardiac issues. Heart failure, particularly in the geriatric population, is a leading cause of this disorder. The treatment for pulmonary edema focuses on managing the underlying heart conditions and reducing fluid buildup in the lungs. Heart treatments include medications like diuretics, vasodilators, and inotropes. Cardiovascular failure, such as that caused by hypertensive crisis or a damaged intra-ventricular septum, can also lead to pulmonary edema. In such cases, disease control through joint ventures, acquisitions, and mergers among healthcare providers plays a crucial role.
Pulmonary edema can be cardiogenic or non-cardiogenic. Cardiogenic pulmonary edema is caused by heart failure, while non-cardiogenic pulmonary edema can result from various conditions, including respiratory syndrome coronavirus. Diagnostic evaluations using Arterial blood gas tests and biomarkers help determine the type and severity of the condition. Treatment involves supplemental oxygen, medicines, and supportive care. Retail pharmacies, hospital pharmacies, and online pharmacies provide access to these treatments. Lung parenchyma, the tissue responsible for gas exchange, and air sacs are affected, making breathing difficult. The prognosis for pulmonary edema depends on the underlying cause and timely intervention.
Market Scope |
|
Report Coverage |
Details |
Page number |
145 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 3.27% |
Market Growth 2024-2028 |
USD 365.5 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
3.13 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Germany, UK, China, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., ADVANZ PHARMA, Apotex Inc., Bausch Health Companies Inc., Baxter International Inc., CHIESI Farmaceutici SpA, CMP Pharma Inc., Emcure Pharmaceuticals Ltd., Epic Pharma LLC, Fresenius Kabi AG, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Teva Pharmaceutical Industries Ltd., Validus Pharmaceuticals LLC, and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.